Scilex Holding Company - Asset Resilience Ratio
Scilex Holding Company (SCLX) has an Asset Resilience Ratio of 6.91% as of March 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read SCLX total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (None–None)
This chart shows how Scilex Holding Company's Asset Resilience Ratio has changed over time. See SCLX total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Scilex Holding Company's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Scilex Holding Company stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $9.68 Million | 6.91% |
| Total Liquid Assets | $9.68 Million | 6.91% |
Asset Resilience Insights
- Limited Liquidity: Scilex Holding Company maintains only 6.91% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Scilex Holding Company Industry Peers by Asset Resilience Ratio
Compare Scilex Holding Company's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AbbVie Inc
NYSE:ABBV |
Drug Manufacturers - General | 0.02% |
|
Roche Holding AG
SW:ROG |
Drug Manufacturers - General | 15.37% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 2.74% |
|
CSPC Pharmaceutical Group Limited
F:CVG |
Drug Manufacturers - General | 4.64% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.03% |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019 |
Drug Manufacturers - General | 0.53% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3 |
Drug Manufacturers - General | 10.10% |
Annual Asset Resilience Ratio for Scilex Holding Company (None–None)
The table below shows the annual Asset Resilience Ratio data for Scilex Holding Company.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| No yearly data available. | ||||
About Scilex Holding Company
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve… Read more